Consistently, the effects of osimertinib on suppressing the growth of both PC‐9 and HCC827 tumors were attenuated since both PC‐9/TRPM2 and HCC827/TRPM2 tumors were significantly less responsive than their corresponding vector control tumors to osimertinib, evaluated by measuring both tumor sizes (Figure 3E,F) and weights (Figure 3G). Here, TRPM2 is linked to neoplasm.